Bevacizumab addition to temozolomide chemotherapy may improve neuroblastoma response
![](https://www.medwirenews.com/wp-content/uploads/2024/02/AdobeStock_203462323-crop.jpg)
Findings from the BEACON-Neuroblastoma trial suggest that adding bevacizumab to temozolomide-based chemotherapy may improve the objective response rate for children with high-risk, relapsed or refractory disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.